Human factor V is activated t o factor Va by a-thrombin after cleavages at Arg", Arg"", and Arg". Factor Va is inactivated by activated protein C (APC) in the presence of a membrane surface after three sequential cleavages of the heavy chain. Cleavage at Arg-provides for efficient exposure of the inactivating cleavages at Arg308 and Arg-. Membranebound factor V is also inactivated by APC after cleavage at Arg308. Resistance t o APC is associated with a single nucleotide change in the factor V gene (G"'+A) corresponding t o a single amino acid substitution in the factor V molecule: Arg-Gln (factor V Leiden). The consequence of this mutation is a delay in factor Va inactivation. Thus, the success of the APC-resistance assay is based on the fortuitous activation of factor V during the assay. Plasmas from normal individuals (1691 GG) and individuals homozygous for the factor V mutation (1691 AA) were diluted in a buffer containing 5 mmol/L CaCI , , phospholipid vesicles ( I O pmol/L), and APC.
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ACTOR V IS A single chain procofactor (molecular F weight [M,] = 330,000) that possesses little or no procoagulant activity.',' At the site of vascular injury, when an appropriate membrane surface is exposed to the blood flow, factor V is activated to its active form, factor Va, by athrombin and factor Xa. The association of factor Va with factor Xa on the membrane forms prothrombinase, the enzymatic complex that activates prothrombin, with an efficiency 5 orders of magnitude greater than factor Xa acting a10ne.~ Factor V is activated by a-thrombin after cleavage at Arg709, ArgI0l8, and Arg1s45.495 a-Thrombin-activated factor Va is composed of a heavy chain (M, = 105,000) containing the NHz-terminal part of the procofactor (residues 1 through 709, AI-A2 domains) and a light chain (M, = 74,000) containing the COOH-terminal part of the factor V molecule (amino acids 1546 through 2196, A3-Cl-C2 domains) that are noncovalently associated in the presence of divalent metal ions.
Recent data show that the plasma of individuals with an Arg506+Gln mutation in the factor V molecule have a poor anticoagulant response to activated protein C (APC), which in turn is associated with a significant increase in risk of developing deep-venous thrombosis (7-fold for the heterozygous and 80-fold for the homozygous).6-10 Membrane-bound factor Va is inactivated by APC after three sequential cleavages of the heavy chain": Arg506, Arg306, and Arg679. Cleavage at ArgSM is necessary for efficient exposure of the inactivating cleavage sites at Arg306 and Arg679. Inactivation of the procofactor, factor V, by APC occurs only in the presence of a membrane-surface and is associated with cleavages at Arg3", Arg' ", Arg67q, and LysqW. The cleavage at Arg306 occurs first and is the inactivating cleavage site. " We have recently shown that natural purified factor VaRSMQ is inactivated by APC at a slower rate than is normal factor Va." In contrast, the procofactor, factor vRSmQ, is inactivated by APC in the presence of a membrane surface with a rate similar to that observed for normal plasma factor V." However, our data suggested that cleavage of the mutant procofactor, factor VRSW, by APC at Arg306 and Arg67q occurs simultaneously. The present study was undertaken to APC, at concentrations 55.5 nmol/L, prevented clot formation in normal plasma, whereas under similar conditions, a clot was observed in plasma from APC-resistant individuals. Gel electrophoresis analyses of factor V fragments showed that membrane-bound factor V is primarily cleaved at Argin both plasmas. However, whereas in normal plasma production of factor Va heavy chain is counterbalanced by fast degradation after cleavage at Argm/Argm, in the APC-resistant individuals' plasma, early generation and accumulation of the heavy chain portion of factor Va occurs as a consequence of delayed cleavage at Arg-. At elevated APC concentrations (>5.5 nmol/L), no clot formation was observed in either ptasma from normal or APC-resistant individuals. Our data show that resistance t o APC in patients with the ArgW+Gln mutation is due t o the inefficient degradation (inactivation) of factor Va heavy chain by APC. visualize how the events occur in whole plasma during the performance of the APC resistance assay. Human protein C was prepared from fresh frozen citrated plasma as described by Bajaj et with the following modifications. The protein C-rich pool from the diethyl aminoethyl (DEAE)-Sepharose column was brought to 75% saturation with ammonium sulfate and stirred overnight at 4°C. The protein C was collected by centrifugation at 5,000g for 30 minutes. The precipitated was suspended in TBS-1 mmoVL benzamidine and dialyzed versus 2 changes of the same buffer. The sample was clarified by centrifugation and applied to a 2.5 x 20 cm column of Q-Sepharose fast flow equilibrated in the same buffer. The column was washed to baseline and then eluted with a linear gradient of 0 to 40 mmoVL CaCI, in the same buffer. Protein C, which elutes at -15 mmol/L CaCl,, is precipitated by 75% ammonium sulfate and collected by centrifugation at 5,OOOg for 30 minutes. The precipitate is dissolved in a minimal volume of 20 mmol/L Tris-Mes, pH 6.0, 1 mmol/L benzamidine. Calcium chloride is added to 2.5 mmol/L and the sample is clarified by centrifugation at 5,OOOg for 15 minutes. The sample is then chromatographed on dextran sulfate agarose as previously de~cribed.'~ The resulting protein C is activated to APC as previously described." It is noteworthy that, whereas all APC preparations had normal esterase activity when using a chromogenic substrate, some of the preparations had low to no anticoagulant activity. Thus, during APC generation, the activity of the enzyme was continuously monitored for its anticoagulant activity rather than for its esterase activity. The reason for the variability in the anticoagulant properties of the APC preparations is unknown and is presently under investigation. Recombinant APC with an alanine instead of a y-carhxyglutamic acid at position 20 (APCyZoA) was obtained as recently described."
MATERIALS AND METHODS

Materials
The chromogenic substrate activity of APC was determined by incubating APC (0 to 100 nmoVL) in a reaction mixture composed of 20 mmol/L Tris/HCl, 0.15 m o m NaC1, 200 mmoVL Spectrozyme PCa (American Diagnostica), pH 7.4, at room temperature. The initial rates of substrate hydrolysis were monitored at 405 nm using a Molecular Devices Corp (Sunnyvale, CA) Vmax microtiter plate reader. Control experiments in which hirudin (25 nmoVL) was incorporated into the reaction mixture ruled out any interference by traces of cy-thrombin. The APCresistance assay was performed as previously detailed.6 Briefly, plasma samples (100 pL) were incubated with the aPTT reagent (100 pL) for 5 minutes at 37°C. Coagulation was initiated by adding 100 pL of solution composed of 20 mmol/L Tris/HCI, 50 mmol/L NaCI, 30 mmol/L CaCI,, 0.1% bovine serum albumin (BSA), pH 7.4, containing varying amounts of plasma APC (0 to 100 nmol/L). The clot time was determined visually.
Immunoblotting of plasma samples. Citrated plasma (100 pL) from normal plasma (pool of 30 donors), a normal individual with a 1691 GG genotype, or 2 APC-resistant individuals with a 1691 AA genotype was diluted 10-fold in HBS(Caz'). Phospholipid vesicles (10 pmol/L) composed of 75% PC and 25% PS were added.
After 2 minutes of incubation at 37"C, purified human plasma APC was added. The clot formation was detected visually. At selected time intervals, aliquots of the mixture were withdrawn (120 pL), mixed with 2% sodium dodecyl sulfate (SDS) and 2% 8-mercaptoethanol, and analyzed on a 4% to 12% (linear gradient) SDS-polyacrylamide gel electrophoresis (SDS-PAGE) according to the method of Laemmli." The proteins were transferred to nitrocellulose'' and probed with either an MoAb that recognizes an epitope located between residues 307 and 506 of the human molecule'z~20 or an MoAb that is directed against the light chain of factor Va. Immunoreactive fragments were visualized using the chemiluminescent substrate Luminol." The immunoreactivity of fragments deriving from factor V (or factor VRSOMI) and factor Va (or factor VaRs06Q) Preparation of protein C and APC.
APC-resistance assay.
for cyHFVaH&6 after incubation with APC are depicted in Fig 1. In some experiments, after clot formation, the samples were centrifuged and aliquots of the supernatant were analyzed by SDS gel electrophoresis.
Human factor V was incubated with either plasma-derived APC or rAPCyZoA in the presence of PCPS vesicles. The concentrations of all reagents are given in the figure legends. At selected time intervals, aliquots of the mixture were assayed for cofactor activity in a clotting time-based assay using factor V-deficient plasma." At the same time intervals, the factor V samples were also analyzed by SDS-PAGE. After electrophoresis and transfer to nitrocellulose, factor V fragments were probed with MoAbs aHFVaH&#6 and/or aHFV#9 using the chemiluminescent substrate Luminol. The potential of contamination by athrombin in the APC preparations was controlled for by the addition of hirudin.
Factor V inactivation studies.
RES U LTS
Variability of the APC-resistance assay. It is well established that factor Va is inactivated after three largely sequential cleavages of the heavy chain," with cleavage at A r c 6 potentiating the inactivating cleavages at Arg306 and at Arg679. Factor V inactivation occurs after a single cleavage" at Arg306. During the APC-resistance assay, citrated plasma is incubated with the aFTT reagent (buffered lipid + contact activator) to allow activation of the intrinsic pathway of blood coagulation that ultimately will result in factor V activation. The lipid composition in the aPTT reagents shown in Fig 2 varies from soybean phospholipid to rabbit brain phospholipid, whereas the factor XI1 activator varies from ellagic acid to micronised silica. Thus, if timely activation of the procofactor does not occur, significant differences in the clotting times for normal plasma and plasma from APCresistant individuals would not be observed, because in both cases factor V will be inactivated with similar rates.
To test the reproducibility of the results of the APC-resistance assay, we performed the assay6 using five different commercially available aPTT reagents. Figure 2A The data presented in Table 1 show the APC ratios when using the APC resistance assay6 and various aPTT reagents (displayed in Fig 2) at two APC concentrations (10 and 20 nmolk) . No significant differences between the APC ratios Thus, the overall variability of the results obtained when using different aPTT reagents can be overcome by the use of low concentrations of APC. It is also important to note that the correlation of the protein concentration to the activity of the APC preparation is also essential for the sake of reproducibility of the results between different laboratories.
In addition to the type of the aPTT reagent, the quality of the APC preparations is critical to the standardization of the APC-resistance clotting assay. All APC preparations, although having similar activities towards chromogenic substrates, do not cleave and inactivate factor Va similarly. The data presented in Fig 3 show this point. Two preparations of APC that were purified from normal pooled plasma (as protein C) and activated to APC using the same protocol were assessed for their ability to cleave a chromogenic sub- APC ratios were determined using the method of Dahlback et strate and to prolong the clotting time of normal plasma. Both preparations possess full chromogenic substrate activity, but only one was capable of prolonging the clotting time of normal plasma ( Fig 3A and B) . Influence of contaminating thrombin on the chromogenic substrate activity was ruled out by the inclusion of 25 n m o K hirudin in the incubation mixture. The example given in Fig 3 is an extreme case of a commonly observed phenomenon from several commercial sources and research laboratories. Although slight differences between these two preparations are detectable by SDS-PAGE analysis (Fig 3C) , the reason for the differences in the anticoagulant activity between the two APC preparations is unknown and presently under investigation. It is clear that elements outside the active site of APC are involved. We have previously devised a protocol (see the Materials and Methods) that consistently produces APC with full anticoagulant activity. When these APC preparations are used in the APC-resistance assay reported by Dahlback et a1,6 APC ratios for normal andor patient plasmas are twofold to threefold higher than those reported. The details of this protocol lead us to speculate that the variant anticoagulant activity of APC preparations may be a property of the lipid binding domain of the APC molecule. The results of these experiments point out the requirement for functional standardization of the APC resistance type assay to confirm the quality of the APC preparations with respect to factor Va cleavage and prolongation of the clotting time. Natural purified factor VaRSMQ is inactivated by purified APC at a slower rate than is normal factor Va." In contrast, the procofactor, factor VR506Q, is inactivated by APC in the presence of a membrane surface with a rate similar to that observed for normal plasma factor V, with cleavages at Arg306 and Arg679 occurring at similar rates." The absence of the APC cleavage site at ArgSo6 of factor Va thus could lead to the accumulation of active cofactor in APC-resistant patients and may be part of the reason for their thrombotic tendencies. Although cleavage at kg306 will inactivate the procofactor,L1,12 our data also suggested that factor VR506Q can also be initially cleaved at Arg679. Cleavage at that position would generate the major portion of the heavy chain (M, = 99,000, amino acid residues 1 through 679). In normal factor V, this product is produced slowly in small amounts and is immediately degraded by APC cleavages at ArgSo6 and Arg306.
To ascertain whether A X can cleave membrane-bound factor VRSMQ initially at Arg679, the inactivation of factor V Leiden7.l2 (1 10 n m o n ) was studied. As one would anticiInactivation of factor v5MQ by APC.
pate, in the presence of 2.2 nmoK APC (Fig 4A, 0 ) the inactivation rate of factor VRSMQ proceeds at a rate faster than that observed in the presence of 550 p m o a APC (m).
Electrophoretic analyses of samples obtained during inactivation of factor VRSmQ by 2.2 n m o n APC showed that inactivation of the procofactor correlates with the transient appearance of an M, = 99,000 fragment, and the appearance of an M, = 54,000 fragment that is accumulated during the inactivation process (amino acid residues 307 through 679, Fig 4B, lanes 12 through 18) . In contrast, at the lower APC concentrations (550 p m o n ) , electrophoretic analyses of the samples obtained after inactivation of factor VR506Q (Fig 4A,  W) showed increased accumulation of the M, = 99,000 fragment and slower formation of the M, = 54,000 fragment ( Fig 4B, lanes 3 through 8) , suggesting that, at lower concentrations of APC, a cleavage fragment that represents a portion of the heavy chain of factor Va (M, = 99,000, amino acid residues 1 through 679) can accumulate. The data show that, after incubation of factor V Leiden with PCPS vesicles and low concentrations of APC, there is appearance of a transient M, = 99,000 fragment (Fig 4B, lanes 4 through 8) .
The potential cofactor activity of factor VRsw and the transient M, = 99,000 fragment disappears as a consequence of cleavage at Arg3% (Fig 4B, lanes 8 and 9) .
In the presence of all concentrations of APC, the M, = 99,000 fragment is transient and disappears as a consequence of cleavage at Arg3% (Fig 4B) . However, cleavage at Arg306 of factor Va by rAPCyZoA is inefficient." Thus, during exposure of factor VR5MQ to rAPC y20A, cleavage of the M, = 99,000 fragment at Arg306 would be delayed, resulting in an increase in the M, = 99,000 fragment and in cofactor activity. To ascertain if membrane-bound factor VRSMQ is activated by APC after cleavage at Arg679, factor VRSw cofactor activity was evaluated using rAPCyZoA in a clotting time-based assay ( Fig 5A) .
Normal plasma factor V is not activated by rAPCYzoA ( Fig  5A, 0) . The gel electrophoresis data shown in Fig 5B (lanes  1 through 9) shows that rAPCyZoA cleaves normal plasma factor V at ArgsM, generating an M, = 75,000 fragment containing the region 1 through 506 of factor V. Cleavage at Arg"' also occurs, resulting in the generation of the M, = 99,000 fragment. Little activity loss (increase in clotting time) is associated with appearance of these fragments. Activity loss (increase in clotting time from 32 to 36 seconds) correlates with the appearance of the M, = 30,000 fragment ( Fig 5B, lanes 7 through 9, arrowhead) showing cleavage at The procoagulant effect of rAPCY2" on factor p5MQ. A$". Thus, in the presence of rAPC'"'", the order of cleavages of membrane-bound normal plasma factor V is reversed, ie, cleavages at Ars" and are followed by slow cleavage at Arg"" and a slow loss in activity.
Slow activation of factor VR51nQ by rAPCY"'" occurs during 2 hours of incubation (Fig SA, a) , which is associated with the accumulation of an M, = 99,000 fragment and a reduction in the clotting time (Fig SA 1  . 1 from 34 to 29 seconds;
and Fig SB, lanes 13 through 18) . The starting factor VR5IffiQ solution (factor V Leiden7.") had a cofactor activity of 1.12 U/mL in the absence of rAPCY2"". After 2 hours of incubation with PCPS vesicles and rAPCY2"", the factor VR5(K'Q solution had a cofactor activity of 1.84 U/mL. Thus, in the presence of rAPCY"'", the factor VR5'HQ solution is 1.64 times more procoagulant than in the absence of rAPCy'"". Electrophoretic analyses (Fig SB) showed generation of an M, = 99,000 fragment. This fragment is most likely a consequence of cleavage at Arg' "' . In normal factor V, the loss in activity associated with the slow cleavage at Arg"" and Arg"" by rAPCY"'" appears to be compensated by activation associated with the generation of the M, = 99.000 portion of the heavy chain (amino acid residues I through 679; Fig SR, lanes 4 through 9,*). In contrast, in factor VR5(KQ there is accumulation of the M, = 99,000 ( Fig SB) as a consequence of impaired inactivation of this fragment by rAPCY?"". Overall, the data suggest that, under certain circumstances, APC can activate factor VR51KQ to a factor VaRSlmQ that would be stable because of delayed cleavage at ArgUK. Thus, whereaq APCY2"" has impaired capability to cleave normal factor V at Arg'", the same molecule cannot cleave and inactivate factor V Leiden because of the absence of the cleavage site at Arg"". Thus, cleavage at Arg5'" may be required for cleavage of the M, = 99,000 factor V heavy chain species. It is noteworthy that, whereas cleavage at Argh79 in factor Va is lipid independent" and is accelerated after cleavage at Arg'", no cleavage of factor V by APC in the absence of a membrane surface was observed when using Coomassie Blue-stained gels." The present data obtained using the more sensitive immunoblotting technique suggest that cleavage of factor V at Arg"" by APC may occur even in the absence of a membrane surface. However, this cleavage is slow under the experimental conditions used; hence, the resulting fragments cannot accumulate sufficiently to be seen on a Coomassie Blue-stained gel and can only be identified using sensitive staining methods (ie, immunoblotting).
Proteolyis of factor V and factor during clotting.
When phospholipid vesicles (10 pmol/L) and Ca" were added to plasma from either normal or APC-resistant individuals, clotting is observed at approximately I O minutes (Table 2 ). Figure 6 depicts the products formed from factor V during the clotting experiment described above visualized with a mixture of aHFVaHc#6 and aHFV-9. Clot formation in plasma from a normal individual (1691 GG genotype; Fig  6A, of factor Va (Fig 6; LC) and of an M, = 75,000 fragment (amino acid residues 1 through 506; Fig 6A, lanes 7 and 8,  arrowhead) . The appearance of the latter is followed by the appearance of a fragment of M, = 30,000 (amino acid residues 307 through 506; Fig 6, lane 8, star) showing cleavage of the heavy chain of normal factor Va at Arg"", followed by cleavage at ArgqW (Fig 6A, lanes 7 and 8) . These data demonstrate, as previously shown," APC generation in plasma after clot formation. Furthermore, no M, = 62,000/ BO7-679) were also analyzed after reduction using 2% pmercaptoethano1 and 2% SDS on a 4% t o 12% linear gradient SDS-PAGE (300 ng of protein were applied per lane). After transfer t o nitrocellulose, the immunoreactive fragments were detected using MoAb aFVa&.
'' Lanes 1 and 10 represent membrane-bound factor VR5m control and no APC; lanes 2 through 9 show membrane-bound factor VRwith 550 pmol/L APC at 1,3,5,10,15, 30,60, and 120 minutes after the addition of APC; and lanes 11 through 18 depict membranebound factor VRin the presence of 2.2 nmol/L APC at the same time intervals as shown in lanes 2 through 9. The position of the molecular weight markers is indicated at left. The positions of the M. = 120,000 fragment containing amino acid residues 1 through 994 and of the M, = 99,000 fragment containing residues 1 through 679 are indicated on the right. 54,000 fragment (amino acid residues 307 through 709/679) is observed in plasma from the APC-resistant individual ( Fig  6B, lanes 6 through 8) , even after extended incubation of patients plasma at 37°C. The data show activation of factor V in plasma from normal and APC-resistant individuals after incubation with Ca" and a membrane surface.
In studies using either normal plasma (pool from 30 healthy donors) or plasma collected from an individual with a normal The effect of APC on factor psmQ in whole plasma.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From Similar results were found in three separate experiments using factor V from patient I (ie, a shortening in the clotting time of approximately 4 seconds was observed after 2 hours of incubation of factor V, and rAPCYzoA). The procoagulant effect of rAPCyZoA is less pronounced when using factor vsm0 from patient 11." (BI The samples assayed for clotting activity in (A) were also analyzed by SDS-PAGE after reduction with 2% p-mercaptoethanol on a 4% t o 12% linear gradient (approximately 250 ng of protein per lane). Fragments were visualized following transfer t o nitrocellulose and staining with aHFVAHe#6. Lane l, normal plasma factor V control, no APC; lanes 2 through 9, normal plasma factor V in the presence of PCPS vesicles and rAPCYzoA after 2, 5, 10, 20, 30, 60,90, and 120 minutes of incubation; lane 10, factor control no APC; lanes 11 through 18, factor Vnma VRm in the presence of PCPS vesicles and rAPCYzoA at the same time intervals as shown in lanes 2 through 9. Lane 19, control, a-thrombin activated factor Va. The positions of the molecular weight markers are indicated on the left. The arrowheads at right depict the position of the M, = 75,000 fragment (amino acid residues 1 through 506) and of the M, = 30,000 fragment that derives from the normal procofactor after cleavage by rAPCYzoA at Arg5ffi followed by slow cleavage at Arg3ffi. The star at the right of lanes 9 and 18 represents the position of a fragment that would derive from normal factor V or factor VR5-after cleavage at Arg"'. The position of the heavy chain of the cofactor (HC; amino acid residues 1 through 709) is also indicated at the right of (6). It is noteworthy that the fragments shown in lanes 3 through 9 and 14 through 18 of (6) (indicated by the star and the arrowheads) are not visible under the conditions used after either Coomassie Blue or silver staining. In different experiments after staining of the gel with silver nitrate, a slight decrease in the concentration of normal factor V is only observed. 
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169 1 GG genotype,' in the presence of a membrane surface, Ca", and 2.8 and 5.5 nmol/L APC, no clot was observed (Table 2 ). Under similar experimental conditions when using whole plasma from APC-resistant individuals homozygous (1691 AA) for the ArgC'"-Gln mutation (patients I and U),'' a clot was noticed (Table 2 ). Figure 7 shows the effect of APC (2.8 nmol/L) on factor V in whole plasma (pool plasma from 30 healthy donors [ Fig 7A] and an APC-resistant individual [ Fig 7B1) in the presence of phospholipid vesicles and Ca". During the first 4 minutes of incubation, a doublet of M, = 330,000/280,000 appears in both normal factor V (Fig 7A, lanes I through 3) and factor VR50hP (Fig 7B, lanes  1 through 3) . showing some cleavage of factor V at Arg"". Subsequently, in normal plasma, there is the appearance of an M, = 30,000 fragment (amino acid residues 307 through 506; Fig 7A, lanes 3 through 5) . Thus, as shown using purified factor V," in normal plasma, factor V is cleaved by APC in the presence of PCPS vesicles at Arg"", followed by cleavage at Arg". The M, --100,000 fragment (Fig 7; HC) most likely represents the heavy chain portion of factor V. This product is rapidly cleaved at Arg"" and Arg' Oh by APC to generate the M, = 30,000 fragment (Fig 7A, lanes  6 through 8) ." These data suggest activation of factor V to factor Va by a-thrombin and/or factor Xa after cleavage at Arg7'" or potentially by APC cleavage at Arg"' and generation of a heavy chain-like product before factor V degradation by APC. The addition of APC and a membrane surface to the plasma from an APC-resistant individual (patient I, APC:SR ratio 1.13)'",'* results in the accumulation of a fragment containing the majority of the heavy chain portion of factor V (HC; Fig 7B, lane 4) . The appearance of this fragment is observed earlier in plasma from APC-resistant individuals than in normal plasma (compare Fig 7A and B, lanes 4 and  5) , and no M, = 30,000" or M, = 54,O0Oi2 fragments are observed after 15 minutes of incubation with APC. As a consequence, this fragment is accumulated during the initial 15 minutes of incubation (Fig 7B, lanes 5 and 6) . Coincidentally, clot formation is observed after 18 minutes of incubation (Fig 7B, vertical arrow) . Similar results were found when using plasma from patient I1 (APC:SR 1.14; Table Figure 8 shows that in normal plasma when APC is added before clot formation the generation of enough heavy chain to support clot formation is impaired. Figure 8A shows the accumulation of heavy chain of factor Va (lanes 1 through 5 ) that results in clot formation at approximately 10 minutes. No clot and no accumulation of heavy chain was observed in the presence of 2.8 and 17 nmol/L APC (Fig 8B and C) .
Furthermore, by increasing the concentration of APC, there is an increase of the M, = 30,000 fragment containing amino acid residues 307 through 506. These data show that clotting in normal plasma is very sensitive to the APC concentration. Figure 9 shows that under similar experimental conditions the heavy chain of factor VaRsohQ is more resistant to APC degradation. Clot formation is observed when APC (at 2.7 and 5.5 nmoVL) is introduced into the plasma from APCresistant individuals (Fig 9B and C) . Collectively, the data show fibrin clot formation in plasma from APC-resistant individuals in the presence of a membrane surface and limited amounts of APC (~5 . 5 nmoVL). After clot formation (Fig 9B and C, fragments a and b) or using higher concentrations of APC (Fig 9D and E, fragments a and b) , there is generation of an M, = 62/56,000 fragment that is generated after cleavage at Arg306/Arg679 of the heavy chain of factor vaR5MQ It is noteworthy that clot formation when using patients' plasma was very sensitive to both the APC preparation and concentration used in each experiment. Similar results were observed with two different APC preparations (ie, in the presence of PCPS vesicles, Ca2+, and 2.8 and 5.5 nmol/L 2). lo.ll plasma APC); a clot was observed in plasma from patient 1 and patient I1 (Table 2) . No clot formation was observed in the presence of higher concentrations of APC ( I 1 and 17 nmol/L) in plasma from APC-resistant individuals. Thus, at high APC concentrations, formation of the active heavy chain is counterbalanced by cleavage of the procofactor at Arg"''. As a result, there is no clot formation.
DISCUSSION
After incubation of plasma with PCPS vesicles and Ca", there is clot formation as a consequence of initiation of the intrinsic and extrinsic pathways of the blood clotting process, resulting in the activation of factor Va. Subsequent to clot formation, there is initiation of the anticoagulant pathway that regulates APC formation and thus factor V N a inactivation. Thus, the relative rates of activationhnactivation of factor V determines the outcome, once a membrane surface and Ca'+ are mixed with plasma. Our data show that the addition of PCPS vesicles, Ca'+, and controlled amounts of APC to diluted plasma from APC-resistant individuals results in the accumulation of the factor Va heavy chain (HC) due to delayed cleavage at Arg3% in the case of membranebound factor VaR506Q. This accumulation of a procoagulant HC leads to clot formation and possibly to the thrombotic tendency manifested in these individuals.
The level of accumulation of HC is regulated by the rate of cleavage at Arg'06 on the membrane-bound factor VRS"6Q/ V(a)R5"6Q and its effect can be observed in plasma in the presence of all proteins that participate in clot formation at a concentration of APC that is compatible with accumulation of enough HC to promote clot formation. Furthermore, the inactivating cleavage at Ar2(I6 occurs first on membranebound factor V, whereas this cleavage is potentiated by prior cleavage at Arg'"' on membrane-bound factor Va. It is noteworthy that whereas empirically determined low concentrations of APC allowed clot formation in plasma from APCresistant individuals, similar concentrations of APC abolish clot formation when introduced in normal plasma before the initiation of clotting.
In plasma from APC-resistant individuals in the presence of PCPS vesicles and Ca2' at low APC concentrations (55.5 nmol/L, Fig 10A) there is early formation of factor Va heavy chain that results in clot formation. Thus, under these conditions, cleavages of factor VRsf'hQ at Arg67' and Arg"" occur at similar rates, resulting in delayed cleavage at Arg"'" and the transient accumulation of HC. No clot formation was observed in normal and APC-resistant individuals at high APC concentrations (>5.5 nmol/L, Fig IOB) . Thus, at high APC concentrations, cleavage at Arg'"', which is responsible for inactivation of factor VR5'"Q, is faster than cleavage at Arg67'. As a consequence, the plasma is rapidly depleted of the factor V(a) pool with procoagulant potential; consequently, there is no generation of HC and no clot formation. Because factor Va and not factor V is procoagulant, the data suggest that, at high APC concentrations (>5.5 nmol/L), cleavage and inactivation of membrane-bound factor V by APC is accelerated and becomes faster than cleavage of the procofactor by a-thrombin and/or factor Xa and generation of active cofactor.
Our present data show that the use of an active APC . After centrifugation, the supernatant was further analyzed by SDS-PAGE, followed by transfer t o nitrocellulose. After transfer t o nitrocellulose, the immunoblot was probed with a mixture of t w o MoAbs, ie, aHFV-9, which recognizes an epitope on the light chain of the cofactor," and aHFVaHc#6, which recognizes an epitope on the heavy chain of factor Va between amino acid residues 307 and 506.'' The position of the molecular weight markers is indicated on the left of (A). The HC at the right of (BI indicates the position of the heavy chain of human factor Va, whereas LC indicates the position of the light chain of factor Va. The arrowhead at the right of (A) indicates the M, = 75,000 fragment deriving from factor Va heavy chain after cleavage at Arg-(amino acid residues 1 through 5061, whereas the star depicts the M. = 30,000 fragment that derives from the M, = 75,000 fragment after cleavage at Arg306 (amino acid residues 307 through 506). HC and LC are given in quotes because the identity of these fragments is inferred from the following: (1) lmmunostaining is performed with a mixture of MoAbs. When used in separate blots, individually, aHNam#6 recognizes an epitope between amino acid residues 307 and 506 of factor V," whereas aHFV-9 recognizes the light chain of the cofactor. Thus, aHFVaHc#6 recognizes factor V, the M. -100,000 heavy chain (amino acid residues 1 through 7091, the M, = 75,000 fragment (amino acid residues 1 through 5061, and the M, = 30,000 fragment (amino acid residues 307 through 506); ' whereas aHFV-9 reacts with factor V, the M, = 220,000 fragment intermediate, and the light chain of factor Va (aHFV-9 has also a slight cross-reactivity with the M, = 150,000 activation peptide of factor V); and (2) in separate experiments using normal plasma or plasma from APC-resistant individuals, the fragment of M, -100.000 migrates at a position that is consistent with the heavy chain of factor Va, whereas the fragment greater than the M, = 75,000 fragment migrates as the light chain of the human cofactor; (3) the appearance of the M. -100.000 fragment is followed by clot formation (see also Fig 7) .
preparation is essential for factor V/factor Va inactivation analysis in whole plasma. In our hands, all APC preparations, although having similar chromogenic activities, do not express similar inactivating properties with respect to factor V N a (shown in Fig 3) . During the standard APC-resistance assay, 100 pL of plasma is incubated with the aPTT reagent for 5 minutes, followed by incubation with APC at concentrations varying from 5 to 100 nmoI/L.' aPTT is composed of a membrane surface and an activator of the intrinsic pathway of blood clotting (activator of factor XII). The inactivation of factor Va is a sequential phenomenon with cleavage at Arg" potentiating cleavage at Arg"Oh,'l.12 whereas membrane-bound factor V is inactivated after cleavage at Arg"'*.
Thus, if the surface is not adequate for factor V binding and/ or if activation of factor V does not occur at high APC concentrations using a fully active APC molecule, both normal plasma factor V and factor VRsMQ would be inactivated with similar rates as a consequence of cleavage at Arg". Thus, an APC-resistant individual will escape detection. In contrast, under similar experimental conditions (ie, in the presence of a less sensitive aPTT reagent and high APC concentrations) using an APC preparation with reduced anticoagulant activity, a difference in the inactivation rates may be observed between normal factor V and factor VRsw. However, this difference will be augmented if the aPTT reagent favors production of factor Va. Thus, the need for M r X l 0 3~ a - 7  8  1  2  3 -' H C " standardization of both the a m reagents and the APC preparations becomes critical with respect to the reproducibility of the results from one laboratory to another. It is noteworthy that, during the standard APC-resistance assay (1/3 diluted plasma as compared with 1/10 diluted plasma in the present study), in plasma from patients homozygous for factor VLeidcn clots are formed even at high APC concentrations."' This phenomenon might be related to both differences in the concentration of the clotting factors and/or the presence of a strong activator of factor XI1 (in the a P l T reagent). Under our experimental conditions, in the absence of APC, the clotting time in our assay is 8 to 10 minutes. This longer clotting time as compared with the standard a m assay (Fig 2) is most likely due to the absence of an activator of the intrinsic pathway of blood coagulation. The longest clotting time shown in Table 2 using limited amounts of APC is greater than 30 minutes. Thus, the clotting time ratio for normal individuals observed using our experimental protocol (>3.0) is not significantly different than that observed using the standard a m -b a s e d screening assay (2.0 to 4.0; Koster et al, 24 Vooberg et al,2s and Table I ). However, our assay uses a membrane surface of known composition (phospholipid vesicles composed of 75% PC and 25% PS), whereas the a m reagents lipid composition is not always defined or described. Thus, in the presence of a bioactive APC preparation (defined in Fig 3) . high reproducibility between different plasma samples would be obtained. Our data also suggests that premature cleavage at Argh79 of the membrane-bound factor VR.WhQ combined with delayed cleavage at Arg30h could result in the accumulation of a shorter heavy chain (amino acid residues 1 through 679). Accumulation of the latter heavy chain portion that most likely possesses procoagulant activity will promote systemic coagulation. These conclusions are partially supported by our data using factor VMw and the AFCymA molecules (Fig 5) . This hypothesis would also explain the shortening of clotting time in plasma from patients homozygous for the Ar$06+Gln mutation in the presence of APC during the recently described new AFC-resistance assay?' The Le et al" suggested that the mechanism of the shortening of the clotting time in patients homozygous for the factor V Leiden mutation may be related to the fact that APC must cleave more than one peptide bond (in the right order) in the factor Va molecule for complete inactivation. Because cleavage at A r p is necessary for efficient exposure of the inactivating cleavage site at Arg-in factor Va heavy chain, we can speculate that production of a portion of the heavy chain of factor Va (by cleavage of factor V R m at Arg6'9) before cleavage at Arg-may generate an APC-resistant heavy chain species in plasma from individuals with factor V Leiden that would require cleavage at Ar$" for inactivation. Whether activation of factor V Leiden by APC is a phenomenon related to cleavage at Arg679 alone or is a combination of events that involves as yet unidentified phenomena that would be potentiated by the Arg%-Gln substitution in factor V remains to be identified. Table 2 (100 pL) was diluted 10-fold in a buffer containing 5 mmol/L CaCI2 and treated with APC in the presence of phospholipid vesicles, as described in the 
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Recently, Bakker et alZ7 reported that cleavage of factor Va at His684 results in a factor Va molecule with diminished cofactor activity. Combination of the data suggests that a more careful characterization of APC-cleaved factor V (at Arg679) is warranted. Thus, verification of the hypothesis mentioned above that cleavage at Arg6" of factor V may increase its cofactor activity needs further investigation and eventually the use of a recombinant factor V molecule with only one available cleavage site for APC (at Arg679).
In conclusion, in APC-resistant individuals, factor VR506U may be rendered procoagulant as a result of cleavage by APC at Arg679. These data, in addition to the data showing delayed inactivation of membrane-bound factor VaRSmQ by reason of slow cleavage at Arg306 resulting in the prolongation of factor Va cofactor activity after clot formation, may explain the thrombotic tendency in individuals with the ArgSo6+Gln substitution. Thus, factor V N a inactivation by APC is a complicated phenomenon governed totally by the kinetics of cleavage at each site as are all clotting reaction~.'~.'~ Recently, a study by Nicolaes et a13' attempted to evaluate the kinetic constants of APC at each cleavage site. However, the results of the latter study are compromised by the high concentrations of enzyme used in their experiments; hence, differences in the inactivation rates when varying the concentration of the reagents are most likely due to the quality and quantity of APC used rather than to the factor Va concentration, as ~uggested.~' Thus, the evaluation of the kinetic constants at each cleavage site in the factor V and factor Va molecule using a bioactive APC preparation and natural and recombinant factor V at physiologic conditions (ie, at low enzyme concentrations) will help the elucidation of the phenomenon of APC resistance. 9. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM: Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 84: 1031, 1994 For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From
